Peptide Profile
Teriparatide
Forteo · PTH 1-34 · Parathyroid Hormone 1-34
Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone, developed as the first FDA-approved anabolic bone agent for…
- Half-life
- ~1 hour
- Routes
- subcutaneous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Teriparatide is
About Teriparatide
Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone
Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone, developed as the first FDA-approved anabolic bone agent for osteoporosis — a compound that stimulates new bone formation rather than merely inhibiting bone resorption. Teriparatide activates the PTH/PTHrP receptor (PTH1R) on osteoblasts; when administered as intermittent pulsatile subcutaneous injections, it drives net bone formation by stimulating osteoblast activity, increasing bone mineral density, improving trabecular microarchitecture, and reducing fracture risk — a distinct mechanism from antiresorptive agents such as bisphosphonates. A comprehensive systematic review and network meta-analysis published in the Annals of Internal Medicine (2023), integrating multiple randomized controlled trials, established teriparatide among the most effective pharmacological interventions for fracture prevention in osteoporosis, with significant reductions in vertebral and non-vertebral fracture risk versus placebo. Teriparatide (Forteo, Eli Lilly) is FDA-approved and requires a prescription; it is indicated for postmenopausal women, men with osteoporosis, and glucocorticoid-induced osteoporosis at high fracture risk, with a maximum treatment duration of two years due to preclinical osteosarcoma findings; biosimilar teriparatide preparations are available in multiple international markets.
Teriparatide Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Teriparatide half-life calculator
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
What the evidence says about Teriparatide
Research Evidence
based on 4 studies · most recent 2026
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- November 26, 2002
- Source
- View FDA source →
FDA-approved parathyroid hormone 1-34 analog. Forteo (NDA 021318, Nov 2002) for osteoporosis. Biosimilar Bonsity (NDA 210842, Jan 2020) also approved. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
4 sources cited · 2 strong · 2 moderate
2 Meta-analysis · 2 Cohorts
The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review.
J Oral Biosci · 2026
# Summary Research found that parathyroid hormone (teriparatide) supplementation consistently improved dental implant integration and peri-implant bone quality in preclinical osteoporotic animal models, with combination treatment approaches showing superior results compared to hormone therapy alone. This study demonstrated that while preclinical evidence supports PTH's potential as an adjunctive strategy to enhance implant outcomes in osteoporotic patients, significant variations in experimental methodologies currently prevent drawing definitive clinical conclusions, necessitating standardized human trials before clinical application.
Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians
Annals of Internal Medicine · 2023
This American College of Physicians network meta-analysis found that teriparatide reduced both clinical and radiographic vertebral fractures in postmenopausal women with osteoporosis and may be more effective than bisphosphonate therapy in very high-risk patients, supporting its established role as an anabolic bone-forming peptide hormone for severe osteoporosis management.
Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adults with osteoporosis: A proportional hazards analysis.
J Orthop · 2026
# Summary This study demonstrated that among osteoporotic adults undergoing lumbosacral fusion, teriparatide showed no significant association with sacral fracture risk in the two-year postoperative period. Researchers observed that vitamin D use was associated with reduced fracture risk, while a history of falls emerged as the strongest predictor of postoperative sacral fracture complications.
Show 1 more source ↓
Biological Augmentation of Reamed Intramedullary Nailing for Aseptic Tibial Shaft Nonunion: An Exploratory Multicenter Retrospective Comparative Cohort Study.
J Funct Morphol Kinesiol · 2026
Teriparatide Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
Reported (unverified — pending clinical review)
No established clinical contraindications
Common monitoring markers in research protocols
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSTeriparatide
Frequently Asked Questions — Teriparatide
Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone, developed as the first FDA-approved anabolic bone agent for osteoporosis — a compound that stimulates new bone formation rather than merely inhibiting bone resorption. Teriparatide activates the PTH/PTHrP receptor (PTH1R) on osteoblasts; when administered as intermittent pulsatile subcutaneous injections, it drives net bone formation by stimulating osteoblast activity, increasing bone mineral density, improving trabecular microarchitecture, and reducing fracture risk — a distinct mechanism from antiresorptive agents such as bisphosphonates.
bone formation, bone density increase, osteoporosis reversal, fracture risk reduction.
Research on Teriparatide primarily documents effects related to bone formation and bone density increase and osteoporosis reversal and fracture risk reduction. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Teriparatide include osteosarcoma risk (2-year limit), Paget's disease, prior radiation to skeleton. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
For Teriparatide, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
1 provider in the directory currently offers Teriparatide.
# Summary Research found that parathyroid hormone (teriparatide) supplementation consistently improved dental implant integration and peri-implant bone quality in preclinical osteoporotic animal models, with combination treatment approaches showing superior results compared to hormone therapy alone. This study demonstrated that while preclinical evidence supports PTH's potential as an adjunctive strategy to enhance implant outcomes in osteoporotic patients, significant variations in experimental methodologies currently prevent drawing definitive clinical conclusions, necessitating standardized human trials before clinical application.
How to get Teriparatide
Where to buy Teriparatide
1 providerCoverage expanding
No providers currently list Teriparatide. Get notified when one does, or explore providers carrying similar peptides in the Longevity category.
Questions to ask your provider
Stay updated on Teriparatide providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.